CHARLES BROWN: Open Payments
NPI 1821176470 · PITTSBURGH, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,051 in 50 payments from 12 companies in 2025. Trend: 2023 $682 · 2024 $1,002 · 2025 $1,051
Food & beverage: $1,051
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 13 | $250 |
| Novo Nordisk Inc | 10 | $193 |
| AstraZeneca Pharmaceuticals LP | 5 | $193 |
| Lilly USA, LLC | 8 | $136 |
| Exact Sciences Corporation | 4 | $91 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $51 |
| PFIZER INC. | 2 | $30 |
| Merck Sharp & Dohme LLC | 2 | $30 |
| Abbott Laboratories | 1 | $23 |
| Organon LLC | 1 | $20 |
Products named: TRELEGY ELLIPTA, AIRSUPRA, Rybelsus, MOUNJARO, Wegovy, Cologuard Collection Kit, FARXIGA, CAPLYTA.
Industry payments across PA — which companies pay providers there.
